Hürthle cell carcinoma: current perspectives.
Journal Article (Review;Journal Article)
Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions <4 cm can be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been observed to be less iodine-avid compared with other differentiated thyroid cancers; however, recent data have demonstrated improved survival with RAI use in patients with HCC >2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC.
Full Text
- Published version (via Digital Object Identifier)
- Pubmed Central version
- Open Access Copy from Duke
- Link to Item
Duke Authors
Cited Authors
- Ahmadi, S; Stang, M; Jiang, XS; Sosa, JA
Published Date
- 2016
Published In
Volume / Issue
- 9 /
Start / End Page
- 6873 - 6884
PubMed ID
- 27853381
Pubmed Central ID
- PMC5106236
International Standard Serial Number (ISSN)
- 1178-6930
Digital Object Identifier (DOI)
- 10.2147/OTT.S119980
Language
- eng
Conference Location
- New Zealand